Moderna Shares Hit 52-Week High as Goldman Raises Price Target
Moderna shares rose sharply on Thursday and reached a fresh 52-week high after Goldman Sachs raised its price target. The move came ahead of full trial data for the company’s cancer vaccine.
Shares of Moderna (MRNA) rose sharply on Thursday, hitting a new 52-week high, after Goldman Sachs raised its price target on the stock, pointing to anticipation for the company’s full trial data on its cancer vaccine.Goldman Sachs analyst Salveen Richter raised the firm’s price target on Moderna t…